BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of investors Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) (AMEX:AMPE) concerning the Company’s and its officers’ possible violations of federal securities laws.
The investigation focuses on whether the Company and its executives violated federal securities laws by failing to disclose that (1) the clinical research organization conducting the STEP Study lacked autonomy; and (2) the trial drug supply for the STEP Study was shipped to clinical sites at lower temperatures than were permitted by the drug’s specifications. As a result of the Company’s fraudulent conduct investors have been severely damaged. On April 20, 2015, Ampio announced that, “the multiple injection STRIDE study AP008 did not reach its primary endpoint against the saline control test.” On this news, shares of Ampio fell $5.18 per share, to close at $2.69, or more than 65.8%, on April 24, 2015.
If you purchased shares of Ampio prior to August 21, 2014, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to email@example.com, or visit our website at http://www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.